# EDGAR Filing Document

**Accession Number:** 0001310527
**File Stem:** 0001493152-23-002395
**Filing Date:** 2023-1
**Character Count:** 6570
**Document Hash:** fd9ab4c6b9d8bf87d3f415863b9ab080
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-002395.hdr.sgml**: 20230125

**ACCESSION NUMBER**: 0001493152-23-002395

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 40

**CONFORMED PERIOD OF REPORT**: 20230125

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230125

**DATE AS OF CHANGE**: 20230125

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** QSAM Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001310527
- **STANDARD INDUSTRIAL CLASSIFICATION:** SPECIALTY CLEANING, POLISHING AND SANITATION PREPARATIONS [2842]
- **IRS NUMBER:** 201602779
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41337
- **FILM NUMBER:** 23550169

**BUSINESS ADDRESS:**
- **STREET 1:** 9442 CAPITAL OF TEXAS HWY N
- **STREET 2:** PLAZA 1, SUITE 500
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78759
- **BUSINESS PHONE:** 512-343-4558

**MAIL ADDRESS:**
- **STREET 1:** 9442 CAPITAL OF TEXAS HWY N
- **STREET 2:** PLAZA 1, SUITE 500
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78759

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Q2Earth Inc.
- **DATE OF NAME CHANGE:** 20170823

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Q2Power Technologies, Inc.
- **DATE OF NAME CHANGE:** 20151215

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Anpath Group, Inc.
- **DATE OF NAME CHANGE:** 20070117

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (date of earliest event reported): January 25, 2023**

**QSAM BIOSCIENCES, INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-41337** | **20-1602779** |
| (State or other jurisdiction | (Commission File | (IRS Employer |
| of incorporation) | Number) | Identification Number) |

---

---

| | |
|:---|:---|
| **9442 Capital of Texas Hwy N** **, Plaza 1, Suite 500** | **78759** |
| (Address of principal executive offices) | (Zip Code) |
| Registrant's telephone number, including area code | **<u>(512) 343-4558</u>** |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| N/A | N/A | N/A |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

| | |
|:---|:---|
| **Item 7.01** | **Regulation FD.** |

---

On January 25, 2023, QSAM Biosciences, Inc. (the "Company") participated in the Emerging Growth Conference. Douglas Baum, our CEO, presented at the virtual conference, using the presentation furnished as Exhibit 99.1 to this report and incorporated herein by reference. The Company may use the presentation and/or webcast of the presentation, possibly with modifications, in future presentations to current and potential investors, analysts, lenders, business partners, acquisition candidates, customers, employees and others with an interest in the Company and its business.

A copy of the presentation is also available on the Company's website at https://ir.qsambio.com/. Materials on the Company's website are not part of or incorporated by reference into this report.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits

The following exhibits are filed with this Current Report on Form 8-K:

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| 99.1 | [QSAM Biosciences, Inc. corporate presentation, dated January 25, 2023.](ex99-1.htm) |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document). |

---

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: January 25, 2023 | QSAM Biosciences, Inc. | QSAM Biosciences, Inc. |
|  | By: | */s/ Douglas Baum* |
|  |  | Douglas Baum |
|  |  | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_002.jpg)

![](ex99-1_003.jpg)

![](ex99-1_004.jpg)

![](ex99-1_005.jpg)

![](ex99-1_006.jpg)

![](ex99-1_007.jpg)

![](ex99-1_008.jpg)

![](ex99-1_009.jpg)

![](ex99-1_010.jpg)

![](ex99-1_011.jpg)

![](ex99-1_012.jpg)

![](ex99-1_013.jpg)

![](ex99-1_014.jpg)

![](ex99-1_015.jpg)

![](ex99-1_016.jpg)

![](ex99-1_017.jpg)

![](ex99-1_018.jpg)

![](ex99-1_019.jpg)

![](ex99-1_020.jpg)

![](ex99-1_021.jpg)

![](ex99-1_022.jpg)

![](ex99-1_023.jpg)

![](ex99-1_024.jpg)

![](ex99-1_025.jpg)

![](ex99-1_026.jpg)

![](ex99-1_027.jpg)